- Home
- HEPS vs SLS Comparison
HEPS vs SLS Comparison
Compare HEPS & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HEPS | SLS |
|---|---|---|
| Founded | 2000 | 2012 |
| Country | Turkey | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 948.0M | 924.5M |
| IPO Year | 2021 | 2007 |
Fundamental Metrics
Financial Performance| Metric | HEPS | SLS |
|---|---|---|
| Price | $2.68 | $5.19 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.07 | ★ $10.00 |
| AVG Volume (30 Days) | 266.4K | ★ 3.9M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $41.29 | N/A |
| Revenue Next Year | $27.99 | $110.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.15 | $1.39 |
| 52 Week High | $3.30 | $6.14 |
Technical Indicators
Market Signals| Indicator | HEPS | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 37.55 | 55.67 |
| Support Level | $2.66 | $4.70 |
| Resistance Level | $2.95 | $5.28 |
| Average True Range (ATR) | 0.07 | 0.26 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 7.50 | 81.73 |
Price Performance
Historical ComparisonAbout HEPS D-Market Electronic Services & Trading
D-MARKET Electronic Services & Trading offers an e-commerce platform in Turkey and the surrounding region. The company is comprised of one reportable segment, namely e-commerce operations. The Group derives revenue from the sales of goods, marketplace revenues and other revenues.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.